LeonaBio upgraded to Outperform from Neutral at Mizuho

Mizuho upgraded LeonaBio (LONA) to Outperform from Neutral with a $10 price target which implies 120% upside potential. The firm upgraded the shares after introducing projections for LeonaBio’s new lead asset lasofoxifene in mutated ESR1/mESR1+ metastatic breast cancer and ATH-1105 for amyotrophic lateral sclerosis. Current investor awareness of LeonaBio “is quite low” following the company’s recent rebranding, the analyst tells investors in a research note. Mizuho sees that changing into the company’s Phase 3 data for lasofoxifene expected in mid-2027.